Pricing
  1. US-listed companies
  2. SELLAS Life Sciences Group, Inc.
  3. Financials
  4. Stock-based compensation

SELLAS Life Sciences Group, Inc. (SLS)

Market cap
$552.77M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20242-25.31%
Dec 31, 20232+21.32%
Dec 31, 20222+70.72%
Dec 31, 20211+74.91%
Dec 31, 20201+0.87%
Dec 31, 20191+45.06%
Dec 31, 20180-87.54%
Dec 31, 20173+39.97%
Dec 31, 20162+17.24%
Dec 31, 20152-64.15%
Dec 31, 20145+112.92%
Dec 31, 20133-87.51%
Dec 31, 201220+7.39%
Dec 31, 201119

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat